Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of March 2020
Date of Report: March 10, 2020
Principal Executive Office: 117 Avenue de Luminy, 13009 Marseille, France
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves as a cover document for a press release and does not contain audited financial statements or detailed financial data within the provided text.
Material Changes
The filing text does not disclose material changes versus prior periods. The document references an attached press release (Exhibit 99.1) dated March 10, 2020, which likely contains the substantive news, but the content of that release is not included in the input text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. These details are expected to be found in the referenced press release (Exhibit 99.1), which is not provided in the source text.
Investor Verification Checklist
- Review the full text of the Press Release dated March 10, 2020 (Exhibit 99.1) to understand the specific event triggering this filing.
- Verify if the press release contains updates on clinical trial progress, regulatory approvals, or partnership agreements, as these are typical for Innate Pharma S.A.
- Check subsequent filings (e.g., Form 20-F or quarterly reports) for the financial impact of any announcements made in March 2020.
- Confirm the company's cash position and burn rate in the most recent available financial statements, as this filing does not provide liquidity data.